DIVA Laboratories Ltd
DIVA Laboratories, Ltd. engages in the development, manufacture, and sale of medical equipment and computer related devices worldwide. The company provides endo/surgical displays, a static and dynamic image for hybrid and integrated ORs applications; color and mono displays for radiology and medical imaging applications; touch displays/human machine interface products; medical and industrial case… Read more
DIVA Laboratories Ltd (4153) - Total Assets
Latest total assets as of June 2025: NT$1.41 Billion TWD
Based on the latest financial reports, DIVA Laboratories Ltd (4153) holds total assets worth NT$1.41 Billion TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
DIVA Laboratories Ltd - Total Assets Trend (2017–2024)
This chart illustrates how DIVA Laboratories Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
DIVA Laboratories Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
DIVA Laboratories Ltd's total assets of NT$1.41 Billion consist of 79.0% current assets and 21.0% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 45.1% |
| Accounts Receivable | NT$262.41 Million | 20.1% |
| Inventory | NT$151.42 Million | 11.6% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$1.71 Million | 0.1% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how DIVA Laboratories Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: DIVA Laboratories Ltd's current assets represent 79.0% of total assets in 2024, an increase from 68.2% in 2017.
- Cash Position: Cash and equivalents constituted 45.1% of total assets in 2024, up from 26.5% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 20.1% of total assets.
DIVA Laboratories Ltd Competitors by Total Assets
Key competitors of DIVA Laboratories Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
DIVA Laboratories Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - DIVA Laboratories Ltd generates 0.66x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, DIVA Laboratories Ltd generates $7.17 in net profit.
DIVA Laboratories Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.71 | 3.36 | 3.43 |
| Quick Ratio | 2.25 | 2.79 | 2.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$715.66 Million | NT$ 742.53 Million | NT$ 671.27 Million |
DIVA Laboratories Ltd - Advanced Valuation Insights
This section examines the relationship between DIVA Laboratories Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.97 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 5.0% |
| Total Assets | NT$1.31 Billion |
| Market Capitalization | $25.67 Million USD |
Valuation Analysis
Below Book Valuation: The market values DIVA Laboratories Ltd's assets below their book value (0.02 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: DIVA Laboratories Ltd's assets grew by 5.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for DIVA Laboratories Ltd (2017–2024)
The table below shows the annual total assets of DIVA Laboratories Ltd from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.31 Billion | +4.96% |
| 2023-12-31 | NT$1.24 Billion | -0.64% |
| 2022-12-31 | NT$1.25 Billion | +5.93% |
| 2021-12-31 | NT$1.18 Billion | +6.15% |
| 2020-12-31 | NT$1.11 Billion | -14.46% |
| 2019-12-31 | NT$1.30 Billion | -1.62% |
| 2018-12-31 | NT$1.32 Billion | +24.61% |
| 2017-12-31 | NT$1.06 Billion | -- |